Skip to main content
Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan

Fig. 4

Overall major adverse-cardiovascular-events free rates for ACEi and ARB users after propensity score weighting. ACEi angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, MACE major adverse cardiovascular events

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840